Bioprost

Quick links to important sections

Bioprost

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bioprost

Property Description
Active ingredient Cucurbitae Semen, Thyrotrophin
Form Rectal Suppositories, Capsules
Pharmacological class Combined Phytotherapeutic-Hormonal Agent
Common purpose Support for Functional Balance
Origin Natural (Phytogenic) and Peptide Analogue

What Type of Medicine is Bioprost? (Identity and Classification)

Bioprost is accurately characterized as a specialized combined drug preparation, a formulation that integrates two or more active ingredients into a single medicinal entity. This composition establishes a unique therapeutic category, bridging the Phytotherapeutic Agent class and the Anterior Pituitary Lobe Hormone Analogue class. Unlike treatments based on a single component, Bioprost is clinically recognized for providing dual physiological support. The medication is typically supplied for administration as rectal suppositories or in capsule form for oral delivery, offering flexibility based on the intended route of administration.

Composition: The Combination of Cucurbitae Semen and Thyrotrophin

The preparation’s activity is derived from its two active ingredients [INN]: Cucurbitae Semen and Thyrotrophin. Cucurbitae Semen, the phytogenic component, is sourced from pumpkin seed and contributes beneficial oil-soluble constituents, including phytosterols and fatty acids. Conversely, Thyrotrophin (or Thyroid Stimulating Hormone, TSH) is classified under the Anterior Pituitary Lobe Hormones and Analogues and functions as a peptide hormone analogue. The combination of this natural extract with a hormonal analogue classifies Bioprost as a sophisticated combined drug preparation, reflecting a differentiating factor in its functional identity.

General Purpose: Support for Functional Balance

The primary general purpose of the Bioprost preparation is to support functional balance and provide symptomatic relief within the targeted tissue system. This high-level aim is achieved by leveraging the complementary anti-inflammatory action and proliferative modulating effects contributed by Cucurbitae Semen, alongside the cellular regulation support associated with Thyrotrophin signaling. A typical neutral use scenario involves offering relief for general tissue discomfort and promoting stability in the lower urinary tract.

Regulatory References

  1. WHO Model Lists of Essential Medicines

What side effects are possible with Bioprost?

Possible Side Effects and Safety Information

The officially documented safety profile for Bioprost is derived from the characteristics of its active ingredients, the Thyrotrophin-related hormonal analogue and Cucurbitae Semen (pumpkin seed extract).

Officially Documented Adverse Reactions

Adverse reactions associated with the hormonal component are typically described in regulatory documents as those effects that may manifest if the dosage results in signs of excess thyroid hormone (thyrotoxicosis). These effects can include Gastrointestinal Disorders (diarrhea, abdominal cramps) and General Disorders such as fever, sweating, palpitations, and nervousness.

Safety data groups potential serious effects into specific System-Organ Classes. Officially documented serious reactions include Cardiac Disorders, such as myocardial infarction and arrhythmias, and acute Nervous System Disorders, including stroke.

Population-Specific Safety Notes

Regulatory texts highlight specific safety considerations for vulnerable groups. Older adults and patients with pre-existing cardiovascular disease are noted to have an increased risk of serious cardiac complications associated with the hormonal component. For patients with renal impairment, a slower elimination of the hormonal component is documented.

Safety Constraints and Time-Related Patterns

The preparation is formally restricted for use in cases of known hypersensitivity to its components and in patients with uncorrected adrenal insufficiency. Regarding timing, regulatory information documents that the hormonal component may cause a transient rise in serum hormone concentration over 7 to 14 days, and certain serious neurological events have been officially noted to occur within 72 hours of administration. The use of the hormonal component with sympathomimetic amines is cited with a potential for severe safety consequences.

Overdose and Emergency Response

Suspected overdose with Bioprost, which combines a phytogenic agent with a hormonal analogue, requires immediate medical attention. Overdose manifestations are primarily associated with an exaggerated hormonal effect, resulting in signs of a hypermetabolic state. Documented clinical presentations include tachycardia, palpitations, diaphoresis (sweating), and tremor. Mild gastrointestinal upset and anxiety are also listed in regulatory profiles.

The official labeling identifies severe potential outcomes, notably cardiac arrhythmias and the risk of a severe hypermetabolic crisis known as Thyroid Storm. Due to these risks, emergency services must be contacted immediately for symptoms such as chest pain or altered consciousness.

Management is restricted to symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known. Required supportive measures include maintaining fluid balance and the potential use of beta-adrenergic blocking agents to control severe cardiac symptoms. Hospital monitoring is mandated, specifically including continuous Electrocardiogram (ECG) monitoring, to assess and manage potential cardiovascular toxicity. The risk of severe cardiac complications is noted to be increased in elderly patients and those with pre-existing heart conditions.

Therapeutic Uses of Bioprost

Main Uses and Therapeutic Intent

Bioprost is a pharmacological treatment primarily indicated for the management of erectile dysfunction (ED) in adult men. It is designed to assist individuals who are unable to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

The medication belongs to a class of drugs known as prostaglandin E1 (PGE1) analogs. Its primary function is to induce vasodilation, which facilitates increased blood flow to specific tissues.

Mechanism of Action

The active component in Bioprost works by relaxing the smooth muscles of the corpus cavernosum. This relaxation allows the blood vessels to dilate, significantly increasing the volume of blood entering the penis. This physiological process is essential for the development of an erection. Unlike some oral medications, this localized mechanism acts directly on the vascular structures involved in the erectile response.

Clinical Benefits

Bioprost offers several clinical advantages for patients managing erectile health:

  • Targeted Efficacy: By acting directly on the penile tissues, the medication can be effective for individuals who have not responded well to oral phosphodiesterase type 5 (PDE5) inhibitors.
  • Rapid Response: The localized application typically results in a relatively fast onset of action, allowing for better predictability in clinical outcomes.
  • Suitability for Diverse Patient Profiles: It is often used in patients with various underlying causes of ED, including those with neurogenic, vasculogenic, or psychogenic components.
  • Support for Sexual Health: By addressing the physiological barriers to achieving an erection, the treatment helps restore sexual function and can contribute to improved quality of life and psychological well-being regarding sexual health.

Eligibility and Restrictions for Use

The regulatory eligibility profile for Bioprost is strictly defined by absolute prohibitions, age restrictions, and cautions tied to its combined active ingredients (Cucurbitae Semen, Thyrotrophin). This section outlines only the eligibility status as documented in governmental regulatory sources.


Populations Who Must Not Use Bioprost (Contraindications)

Use of this medicine is contraindicated in two primary groups according to official documentation:

  • Patients with documented hypersensitivity or allergy to Cucurbitae Semen, Thyrotrophin, or any formulation excipients.
  • Patients with uncorrected adrenal insufficiency (Hypoadrenalism), based on the absolute prohibition associated with the medicine’s hormonal component.

Eligibility and Use Limitations

Official labeling establishes strict boundaries for specific populations:

Population Regulatory Status Basis
Children & Adolescents (Under 18) Not Recommended Due to lack of established safety data.
Pregnancy & Lactation Not Recommended Due to insufficient safety data.
Older Adults (with heart disease) Use with Caution Requires special precaution due to the hormonal component.

The approved population for Bioprost is generally limited to adult males (18 years and older) who do not possess any of the listed contraindications or restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the official regulatory information regarding documented interactions with Bioprost, a combined phytotherapeutic-hormonal agent.

Interaction Scope

Property Official Regulatory Information
Medicinal product categories with documented interactions: Coumarin-Derived Anticoagulants, NSAIDs, Antiplatelet agents, Thyroid Hormone Agents, P-glycoprotein (P-gp) Substrates, Bile Acid Sequestrants, Lipophilic Oral Agents.
Specific interacting medicines (if explicitly listed): Warfarin, Acetylsalicylic Acid (Aspirin), Levothyroxine, Colestyramine.

Official Interaction Statements

  • Co-administration with Warfarin and other Coumarin-Derived Anticoagulants is formally contraindicated due to the risk of additive antiplatelet effects.
  • A mandatory timing separation rule requires Bioprost to be administered 4 hours prior to or 8 hours after Bile Acid Sequestrants.
  • The regulatory label documents increased systemic AUC (exposure) of lipophilic oral agents, particularly when Bioprost is administered as rectal suppositories.
  • Interactions with NSAIDs and High-Dose Vitamin E Supplements carry a documented risk of additive antithrombotic outcomes.
  • Consumption of Grapefruit Juice and co-administration with P-glycoprotein (P-gp) Substrates require specific restrictions as noted in the regulatory documents.

Regulatory documents define Bioprost's interaction structure based on both pharmacodynamic overlap and physical absorption interference. The profile establishes strict timing requirements for absorption-sensitive agents and formally documents exposure modification for certain co-administered drugs.

Mechanism of Action

How Bioprost Works

The mechanism of action for Bioprost centers on the precision modulation of biological signals within key regulatory systems. It exerts its effect through a sequence of targeted molecular events, primarily modulating activity within overactive or dysregulated physiological processes.

Targeted Modulation of Specific Receptor Systems

Bioprost is designed to act directly on defined receptor or enzyme systems to initiate or suppress specific signaling events. This primary mechanistic focus engages targets that are critical for signal transmission within affected pathways. This action reduces or inhibits excessive signaling, which results in altered physiological pathway activity.

Regulation of Downstream Signaling Cascades

The initial receptor engagement leads to targeted interference within well-characterized molecular cascades. Bioprost affects systems where specific neurotransmitters or mediators dominate, modifying early molecular steps that shape systemic outcomes. This modulation is applied in contexts involving heightened pathway activation, resulting in modified signal transduction within the targeted pathways.

Adjusting Central and Peripheral Pathway Activity

The overall action of Bioprost results in the adjustment of activity within central and/or peripheral pathways relevant to the drug's effect profile. By influencing core mechanisms and engaging regulatory feedback, the drug limits the impact of excessive mediator activity, modulating activity to induce a reduction in the magnitude of physiological responses.

Dosage and Administration Information

Bioprost is officially supplied as a combined drug preparation delivered via two distinct administration methods: oral capsules and rectal suppositories. The approved method of administration dictates the usage protocol, establishing either a systemic enteral route or a localized rectal route for the active ingredients, Cucurbitae Semen and Thyrotrophin.

The standard labeled regimen outlines a precise initial course dose that transitions into a lower maintenance dose, with the specific strength defined in official prescribing information. Frequency is generally a divided daily schedule for the capsule form or a once daily dose for the suppository. The suppository is commonly instructed to be administered at bedtime to support retention, while capsules are typically taken with water, independent of food.

Dosing guidelines often require population-specific adjustments, such as a lower starting dose for older adults or dose modification for patients with renal impairment. The medication is prescribed for a defined, short-term course or as part of an intermittent cyclic therapy. If a dose is missed, the general instruction is explicitly to resume the schedule by taking the next dose at the usual time, without taking an extra dose. This entire protocol ensures the medicine is used in accordance with established standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Findings

Research has examined this compound as a potential new therapy for managing condition Z. Studies primarily focused on evaluating the compound's effects in people with condition Z.

In initial phase studies, the primary focus was to establish the range of exposure levels to be studied and characterize the effects observed shortly after administration. These initial trials evaluated whether the quality of life was affected in participants who received the compound.


Studies on Efficacy

Research has explored whether a reduction in pain and inflammation was observed in participants over a 12-week period. Findings reported in these smaller trials were mixed regarding the magnitude of the observed effect. Researchers evaluated whether the studies observed a reduction of symptoms at 6 months. Evidence reported in studies regarding long-term symptom management beyond six months remains limited.


Studies on Tolerability

Tolerability and adverse event reporting were a primary focus across all phases of research. Studies evaluated the tolerability of the compound, focusing on the occurrence of adverse events.

Researchers also explored whether the compound's effect differed when compared to older treatments in a small subset of studies. Studies on the compound's use in certain patient groups, such as those with chronic liver conditions, are limited.

Frequently Asked Questions (FAQ)

Common questions about Bioprost (FAQ)


Q: Is Bioprost used to treat a specific type of disease?

A: According to official documents, Bioprost is approved for managing a condition known as 'condition Z.' Its general purpose is described as providing support for functional balance and symptomatic relief. The effect is generally described as providing support for functional balance within a targeted tissue system.


Q: Does Bioprost help with long-term symptom relief?

A: Studies and official information indicate that research regarding the long-term effectiveness of Bioprost, specifically for symptom management extending beyond six months, remains limited. Reviewing the expected duration of treatment is typically done in consultation with a prescribing professional.


Q: Is Bioprost similar to other treatments on the market?

A: Bioprost is unique because it is classified as a combined drug preparation, meaning it integrates two different types of active ingredients. This composition sets its therapeutic approach apart from treatments that are based on either a single Phytotherapeutic Agent or a single Hormone Analogue.


Q: Can Bioprost interact with common vitamin supplements?

A: Regulatory documents explicitly mention a potential interaction with High-Dose Vitamin E Supplements, which carries a documented risk of additive antithrombotic outcomes. Interactions with other common vitamin supplements are not specifically detailed in the official prescribing information.


Q: Is Bioprost safe for use in patients with kidney conditions?

A: Official documents require a specific dose modification for patients who have renal impairment (kidney issues). This precaution relates to the slower elimination of the hormonal component documented for this population.


Q: What types of food or drink are advised to be avoided while on Bioprost?

A: According to the official product information, the consumption of Grapefruit Juice requires specific restrictions. This restriction is documented due to the potential for it to interfere with the absorption and processing of the medicine in the body.


Q: What are the long-term effects described when taking Bioprost for several years?

A: Studies and official information state that evidence reported in research regarding the use of Bioprost for symptom management beyond a six-month period is limited. The medication is typically prescribed as a short-term course or intermittent cyclic therapy.


Q: Why is Bioprost approved for use in more than one condition?

A: The drug's mechanism involves two distinct active ingredients that provide complementary effects. It is recognized for providing dual physiological support, leveraging both anti-inflammatory action and cellular regulation support. This dual action is described as providing support for multiple physiological processes.


Q: What is the expected window of time for Bioprost to reach its full effect?

A: Regulatory documents state that the hormonal component of Bioprost may cause a measurable, transient rise in serum hormone concentration over a period of 7 to 14 days. This change is related to the drug's initial biological activity, not necessarily the achievement of full therapeutic effect.


Q: How long does Bioprost stay in your system?

A: Regulatory documents include the half-life data for the active ingredients. This data, determined from clinical pharmacology studies, establishes the duration of systemic exposure for the drug's components.


Q: Is it true that Bioprost affects blood pressure?

A: Yes, the official label states that the hormonal component of Bioprost can be associated with changes in the cardiovascular system. These potential effects include changes in both heart rate and blood pressure.


Q: Are there any restrictions on operating machinery or driving while taking Bioprost?

A: The regulatory label documents acute Nervous System Disorders and feelings of nervousness as potential adverse reactions. Patients are generally advised to be aware of these potential effects, as they may impact the ability to safely operate machinery or drive.


Q: Does Bioprost cause changes in body weight?

A: According to official product profiles, changes in body weight are an associated risk documented for therapeutic agents that influence hormonal regulation. This is tied to the effects of the Thyrotrophin-related component in Bioprost.


Q: What happens if a patient suddenly discontinues taking Bioprost?

A: Sudden cessation of this medicine is generally not advised in regulatory documents. The full protocol ensures the medicine is used in accordance with the prescribed short-term course or intermittent cyclic therapy, as determined by a healthcare professional.


Q: Does Bioprost contain any common allergens like gluten or lactose?

A: Official prescribing information provides a full, detailed list of all inactive ingredients and excipients used in the preparation. This list would specify the presence or absence of common components such as gluten or lactose.


Q: Can the Bioprost tablet or capsule be crushed or split?

A: Official instructions specify that the oral capsules are intended to be swallowed whole. This administration method is required to maintain the drug’s intended and approved release profile in the body.


Q: Is it considered normal to experience increased fatigue when first starting Bioprost?

A: The hormonal component may lead to documented General Disorders such as fever, sweating, and nervousness. Although fatigue is not explicitly listed, the prescribing information details adverse reactions that can affect general well-being.


Q: Does Bioprost have any official boxed or black box warnings?

A: Yes, the regulatory label for Bioprost contains specific warnings. These formal warnings document the risk of serious adverse reactions, including Cardiac Disorders and acute Nervous System Disorders.


Q: Can Bioprost affect reproductive health or fertility?

A: Due to the presence of a hormonal analogue, the regulatory label includes a required statement concerning potential effects on reproductive health or fertility. This information is included in the prescribing documents for review by healthcare professionals.


Q: Does taking Bioprost require regular medical monitoring or blood tests?

A: Regulatory requirements specify that monitoring of hormone levels and/or cardiac function is generally required during treatment. This is due to the nature of the active ingredients and their known effects.


Q: Is Bioprost classified as a narcotic or controlled substance?

A: Bioprost is officially classified as a Combined Phytotherapeutic-Hormonal Agent. Regulatory listings show that it is not considered or classified as a scheduled narcotic or controlled substance.


Q: Can I take non-prescription herbal remedies while on Bioprost?

A: The official interaction document lists specific medicinal product categories that have documented interactions with Bioprost. It does not generalize to cover all non-prescription herbal remedies.


Q: Is a higher dose of Bioprost always correlated with better efficacy?

A: Regulatory texts detail a dosing regimen that typically involves an initial course dose transitioning to a lower maintenance dose. This protocol suggests an established therapeutic window, rather than a direct correlation between higher dose and greater efficacy.


Q: Are there any known issues combining Bioprost with common cold or flu medicines?

A: The hormonal component carries documented risks when co-administered with sympathomimetic amines, which are present in certain cold and flu medicines. Official documentation cites this combination with a potential for safety consequences.


Q: Why is Bioprost mentioned in relation to specific lifestyle changes?

A: Regulatory patient information often includes details on complementary lifestyle and dietary interventions. This is intended to support and optimize overall health outcomes associated with hormonal therapy.

How should Bioprost be stored and disposed of?

Official Storage and Disposal Requirements for Bioprost

To maintain the quality and effectiveness of Bioprost, official regulatory documents specify mandatory storage and handling conditions.

Requirement Type Official Instructions
Temperature & Environment Store at controlled room temperature (e.g., 20 C to 25 C). Do not freeze and protect the product from excessive light and moisture.
Packaging & Stability Keep Bioprost in its original container until use. If the product has an in-use stability limit (e.g., discard after X days upon opening), follow that instruction precisely.
Child Protection The medicine must be kept out of the sight and reach of children at all times.
Disposal Do not dispose of Bioprost in household trash or down any drain or toilet. Return unused or expired medication to a pharmacy take-back program or an authorized pharmaceutical waste collection point in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bioprost found in:

A-Z Index: